INTRODUCTION
============

The majority of patients with colon cancer are stage II or III at diagnosis; of these, 30%--40% are stage II colon cancer (T3/ T4N0M0) \[[@b1-ac-2018-12-04], [@b2-ac-2018-12-04]\]. Fluorouracil (5-FU) based adjuvant chemotherapy (AC) for stage III colon cancer improved 5-year survival rates \[[@b3-ac-2018-12-04]\]. However, AC remains controversial for patients with stage II colon cancer. Patients with stage II colon cancer have good prognosis, with an overall survival (OS) rate higher than 60%--80% \[[@b4-ac-2018-12-04], [@b5-ac-2018-12-04]\]. Previously, the OS benefit in stage II colon cancer treated with AC was not prominent \[[@b6-ac-2018-12-04], [@b7-ac-2018-12-04]\]. However, other studies have shown that 5-FU treatment improves survival for patients with stage II colon cancer. The National Surgical Adjuvant Breast and Bowel Project group reported a 30% reduction in mortality, and subgroup analysis showed significant benefits in groups with poor prognoses \[[@b8-ac-2018-12-04]\].

Surgical oncologists in other gastrointestinal groups occasionally judge the surgical and pathologic stages differently and determine chemotherapy use accordingly \[[@b9-ac-2018-12-04]\]. The opinion of the operating surgeon is essential in evaluating a patient's cancer status. Similarly, colorectal surgical oncologists may consider a patient's peri-operative status and postoperative course in determining use of AC.

The purpose of this study was to develop criteria to aid surgical oncologists with decisions regarding the use of AC, to investigate factors affecting the survival rate of stage IIa colon cancer, and to understand the role of chemotherapy in high- and low-risk groups.

METHODS
=======

Between January 2004 and December 2010, patients underwent curative resection in one of 6 hospitals (Seoul St. Mary's Hospital, Yeouido St. Mary's Hospital, Uijeongbu St. Mary's Hospital, Incheon St. Mary's Hospital, St. Vincent's Hospital, Daejeon St. Mary's Hospital College of Medicine) within the Catholic Medical Center and were enrolled in this study. Of 1,785 patients with stage II and III colon cancer, 736 patients with stage IIa (T3 N0M0) colon cancer were prospectively collected in the CMC colorectal cancer database, and survival outcomes were confirmed via retrospective chart review.

Histologic stage was based on the 7th American Joint Committee on Cancer/Union for International Cancer Control TNM classification. A specialized colorectal surgeon performed all operations and administered chemotherapy. Clinical data were recorded in detail, including patient demographic information, operation data, morbidity, pathology, recovery, recurrence, and survival. Tumor location was classified as cecum, ascending colon, hepatic flexure, transverse colon, splenic flexure, or sigmoid colon. The high-risk group was determined by the presence of at least one of the following factors: obstruction and/or perforation, lymphatic invasion, vascular invasion, perineural invasion, positive margins, poorly differentiated histology, and less than 12 harvested LNs. The low-risk group was defined by absence of the above risk factors, and the high-risk group consisted of patients with one or more of these risk factors.

Surgical oncologists made decisions regarding AC using clinical judgement following curative resection. A surgical oncologist was defined as a surgeon who provides surgery and AC. General performance, pathologic features, and postoperative condition of the patient were considered. AC was usually a 6-month course of 5-FU based treatments. All patients were continuously followed after surgery. During the initial year following surgery, follow-up was performed at 3-month intervals. This was followed by 6-month intervals for 3 years following surgery and then a 1-year interval for final follow-up. Follow-up examinations included physical examination, rectal examination, carcinoembryonic antigen (CEA) level, chest X-ray, abdominal ultrasonography, abdominal computed tomography (CT), and colonoscopy.

When recurrence was suspected, chest CT and positron emission tomography-CT were performed. Recurrence was defined as histologic confirmation at the recurrence site or increased lesion size and deterioration of the lesion.

Follow-up results up to February 2015 were included in this study. The Institutional Review Board (IRB) number of this study is XC15RIMI0038-KSUOVD. The IRB waived informed consent for this study.

Statistical analysis
--------------------

Differences between categorical variables were analyzed using the chi-square test. The prognostic significance of demographic and pathologic characteristics was determined using univariable and multivariable Cox proportional hazard regression analyses.

Statistical analyses were performed using IBM SPSS ver. 18.0 (IBM Co., Armonk, NY, USA). A Kaplan-Meier survival curve was constructed, and the log-rank test identified statistically significant differences in survival. Variables that reached statistical significance (P \< 0.05) were entered into a multivariate analysis, which was performed using the Cox proportional hazard model. In all cases, P-values less than 0.05 were considered statistically significant.

RESULTS
=======

Patient characteristics
-----------------------

The median follow-up of the whole group was 56.5 months (range, 1--130 months). Of 736 patients with stage IIa colon cancer (T3N0M0) who underwent curative resection, 534 patients (72.6%) received 5-FU based AC, and 202 patients (27.4%) only received surgery. At the time of diagnosis, median age was 64.5 ± 12.1 years, 284 patients (38.6%) were over 70 years old, and 428 patients (58.2%) were male. Preoperative CEA was 9.58 ± 39.03 ng/mL

In the chemotherapy group, patients were significantly younger and had higher BMI, lower American Society of Anesthesiologists (ASA) physical status classification, lower postoperative complications, higher histologic grade, and shorter hospital stay. Vascular invasion was higher in the surgery-only group.

There was no significant difference in factors of the high-risk group except for poorly differentiated histology. The proportion of patients in the high-risk group was not different between the AC and non-AC groups (59.4% vs. 59.4%, P = 0.99) ([Table 1](#t1-ac-2018-12-04){ref-type="table"}).

Cancer-related survival & prognostic factors
--------------------------------------------

Five-year OS was 90.1%, and DFS was 90.3%. For those receiving chemotherapy (CTx), the difference in OS (CTx+: 92.4% CTx−: 84.5%, P = 0.003) and DFS (CTx+: 91.3% CTx−: 84.6% P = 0.006) was confirmed ([Fig. 1](#f1-ac-2018-12-04){ref-type="fig"}).

Univariate analysis of prognostic factors that might affect survival was performed. Younger age and AC had a positive effect on survival, while higher BMI, preoperative CEA above 5 ng/mL, obstruction and/or perforation, fewer than 12 harvested LNs, and high-risk group had a negative effect on either DFS or OS. Postoperative complications affected DFS, and male sex affected OS.

In the multivariate analysis, older age, higher BMI, and obstruction and/or perforation had a negative impact on DFS. Male sex, higher BMI, preoperative CEA above 5 ng/mL, obstruction and/ or perforation, and fewer than 12 harvested LNs had a negative impact on OS. The results of univariate analysis showed that high-risk characteristics were substantial predictors of DFS and OS. AC was also a significant predictor of DFS and OS in univariate analysis, but not in multivariate analysis ([Tables 2](#t2-ac-2018-12-04){ref-type="table"}, [3](#t3-ac-2018-12-04){ref-type="table"}).

Chemotherapy-related survival & prognostic factors
--------------------------------------------------

Patients were divided into an AC group (534 patients, 72.6%) and a surgery-alone group (202 patients, 27.4%) according to their treatment path.

In the chemotherapy group, BMI (hazard ratio \[HR\], 1.18; 95% confidence interval \[CI\], 0.7--0.95; P = 0.040), preoperative CEA (HR, 2.02; 95% CI, 1.17--3.46; P = 0.011), distal resection margin (DRM) (HR, 0.926; 95% CI, 0.87--0.97; P = 0.006), and harvested LN count (HR, 0.96; 95% CI, 0.94--0.99; P = 0.040) were significant predictors of DFS. BMI (HR, 1.15; 95% CI, 0.78--0.98; P = 0.021) and ASA physical status classification (HR, 2.02; 95% CI, 1.37--11.20; P = 0.011) were significant predictors of OS.

In the surgery-alone group, ASA physical status classification (HR 3.42; 95% CI, 1.06--11.03; P = 0.039) was a significant predictor of DFS, while harvested LN count (HR 0.107; 95% CI, 0.031--0.374; P \< 0.001) was a significant predictor of OS ([Tables 4](#t4-ac-2018-12-04){ref-type="table"}, [5](#t5-ac-2018-12-04){ref-type="table"}).

Cancer-related survival in high-risk vs. low-risk groups
--------------------------------------------------------

Factors related to OS and DFS were identified in the high-risk group (n = 436, 59.2%) and low-risk group (n = 300, 40.8%).

In univariate analysis of the high-risk group, age, BMI, ASA physical status classification, harvested lymph node (LN) count, and AC were significant predictors of OS. Among these factors in multivariate analysis, BMI (HR, 1.37; 95% CI, 0.61--0.86; P \< 0.000) and harvested LN count (HR, 0.94; 95% CI, 0.89--0.98; P = 0.017) had a significant effect on OS.

AC was a significant predictor of OS in univariate analysis in the high-risk group, but this effect was only a trend in multivariate analysis (HR, 0.59; 95% CI, 0.33--1.07; P = 0.086). In the low-risk group (300 patients, 40.8%), there were no significant associations observed in the multivariate analysis. There were no statistically significant predictors of DFS within the high-risk and low-risk groups ([Tables 6](#t6-ac-2018-12-04){ref-type="table"}, [7](#t7-ac-2018-12-04){ref-type="table"}).

DISCUSSION
==========

Kumar et al. \[[@b10-ac-2018-12-04]\] recommend adjuvant treatment for patients with stage II colon cancer if there are inadequately sampled nodes, T4 lesions, perforation, or poorly differentiated histology. Microscopically, chemotherapy destroys cancer cell deposits and possibly eliminates hidden metastasis. This recommendation may also be beneficial due to other lesser-known factors. For example, good baseline prognosis in the stage II group, noncancer related death in elderly patients, and inappropriate staging due to improper node resection suggest that the benefit of AC may be masked \[[@b10-ac-2018-12-04], [@b11-ac-2018-12-04]\].

One study of radically resected stage pT3-pT4b gastric cancers suggests that there may be a discordance between surgical stage and pathologic stage, and surgical stage may be an independent factor affecting OS. Surgical T stage is a significant and independent prognostic index of OS in patients with radically resected advanced gastric cancer \[[@b9-ac-2018-12-04]\]. Based on these results, the operating surgeon's opinion is essential in evaluating a patient's cancer status.

In a previous study, overall 5-year survival for patients with T3N0 cancer was 60%--80% \[[@b4-ac-2018-12-04], [@b5-ac-2018-12-04]\]. The results of this study found significantly higher rates for 5-year OS (90.1%) and DFS (90.3%) compared to previous studies. The surgical oncologist in our study used AC and wanted to determine characteristics of the group, which could have resulted in these differences. However, the scientific evidence for this hypothesis is weak and needs further study.

In the present study, the chemotherapy group was significantly younger and had higher average BMI, lower ASA physical status classification, lower postoperative complications, and higher histologic grade than the surgery-alone group. These findings differ from generally known high-risk factors, and surgical oncologists in our study were less likely to use high-risk factors and more likely to consider the patient's intraoperative and postoperative conditions in determining AC use. Considering that DRM and less than 12 harvested LNs are significant factors, incomplete curative resection is one factor considered in determining the use of AC.

Surgical oncologists have the advantage of evaluating a patient's condition directly in the operating room while performing surgery, which is different from reported pathologic results and studies such as ascites tumor maker analysis \[[@b12-ac-2018-12-04]\]. In addition, patients are observed during the recovery period after surgery, and AC is decided on by careful consideration of the patient's condition after an outpatient visit. Therefore, these encounters are advantageous for surgical oncologists performing AC.

Factors affecting survival rate in the chemotherapy group were BMI, preoperative CEA, and harvested LN counts. CEA is often recommended as a prognostic factor with preoperative testing, and elevated CEA is associated with poor prognosis \[[@b13-ac-2018-12-04]\]. In this study, elevated CEA levels above 5 ng/mL also significantly affected survival rate in multivariate analysis.

Harvested LN count is affected by anatomical structure, resection range, and surgical technique, which are considered surrogates for complete resection of tumor bearing tissue. The 5-year survival rate of the National Cancer Database for T3N0 colon cancer with 35,787 cases was 64% (1--2 LN examined) and 86% (\>25 LN examined), and there was also a 5-year survival rate difference according to classification of LN harvest count (1 to 7, 8 to 12, 13 or more). The mean number of LNs examined in this study was 21.36 ± 12.72, and 152 patients (20.7%) had less than 12 harvested LNs. Survival rate was negatively impacted when less than 12 LNs were harvested.

Recurrence after curative operation may be due to micrometastasis at the time of surgery. AC aims to increase the cure rate by reducing micrometastasis. In stage III cancer, AC is reasonable and logical due to LN infiltration. It is important to identify poor prognostic factors associated with latent micrometastasis in stage II. This study suggests that risk factors for lowering survival rate are preoperative CEA above 5 ng/mL, obstruction and/or perforation, and fewer than 12 harvested LNs. Although multivariate analysis showed that AC was not an independent factor, further study is needed because of the tendency noted in the high-risk group.

In conclusion, surgical oncologists in our study tend to consider a patient's perioperative condition and postoperative status rather than high-risk factors when determining AC use. AC might be considered for patients in the high-risk group, but this study did not show significant effects in multivariate analysis. More large volume and prospective studies are needed to further address this issue with strong evidence.

No potential conflict of interest relevant to this article was reported.
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###### 

Patient characteristics

  Variable                             Total (n = 736)   CTx-- (n = 202)   CTx+ (n = 534)   P-value
  ------------------------------------ ----------------- ----------------- ---------------- ---------
  Age (yr)                             64.49 ± 12.05     69.04 ± 12.65     62.7 ± 11.36     \<0.001
  Age (yr)                                                                                  \<0.001
   ≤70                                 452 (61.4)        95 (47)           357 (66.9)       
   \>70                                284 (38.6)        107 (53)          177 (33.1)       
  Sex                                                                                       0.929
   Male                                428 (58.2)        118 (58.4)        310 (58.1)       
   Female                              308 (41.8)        84 (41.6)         224 (41.6)       
  Body mass index (kg/m^2^)                              22.7 ± 3.48       23.2 ± 3.08      0.034
  Preoperative CEA (ng/mL)             9.58 ± 39.03      9.52 ± 41.03      9.61 ± 38.2      0.980
  Preoperative CEA (ng/mL)                                                                  0.078
   ≤5                                  579 (78.7)        163 (80.7)        416 (77.9)       
   \>5                                 157 (21.3)        39 (19.3)         118 (22.1)       
  ASA physical status classification                                                        \<0.001
   I                                   258 (35.1)        53 (26.2)         205 (38.4)       
   II                                  430 (58.4)        123 (60.9)        307 (57.5)       
   III                                 45 (6.1)          25 (12.4)         20 (3.7)         
   IV                                  3 (0.4)           1 (0.5)           2 (0.4)          
  Lap                                                                                       0.105
   Laparoscopic                        400 (54.3)        100 (49.5)        300 (56.2)       
   Conventional                        336 (45.7)        102 (50.5)        234 (43.8)       
  Obstruction and/or perforation                                                            0.309
   Negative                            628 (85.3)        168 (83.2)        460 (86.1)       
   Positive                            108 (14.7)        34 (16.8)         74 (13.9)        
  Postoperative complication                                                                0.018
   Negative                            640 (87)          166 (82.2)        474 (88.8)       
   Positive                            96 (13)           36 (17.8)         60 (11.2)        
  Tumor size (cm)                                        5.30 ± 2.3        5.56 ± 2.41      0.170
  DRM (cm)                                               11.6 ± 8.7        10.7 ± 6.9       0.170
  PRM (cm)                                               15.4 ± 12.7       15.24 ± 30.9     0.940
  Harvested LN                                           21.4              21.3             0.960
  Harvested LN                                                                              0.790
   \<12                                152 (20.7)        43 (21.3)         109 (20.4)       
   ≥12                                 584 (79.3)        159 (78.7)        425 (79.6)       
  Histologic grade                                                                          0.001
   Well to moderate                    609 (82.7)        183 (90.6)        426 (79.8)       
   Poorly/undifferentiated             127 (17.3)        19 (9.4)          108 (20.2)       
  Neural invasion                                                                           0.350
   Negative                            623 (84.6)        175 (86.6)        448 (83.9)       
   Positive                            113 (15.4)        27 (13.4)         86 (16.1)        
  Vascular invasion                                                                         0.040
   Negative                            709 (96.3)        190 (94.1)        519 (97.2)       
   Positive                            27 (3.7)          12 (5.9)          15 (2.8)         
  Lymphatic invasion                                                                        0.370
   Negative                            626 (85.1)        168 (83.2)        458 (85.8)       
   Positive                            110 (14.9)        34 (16.8)         76 (14.2)        
  High risk                                                                                 0.990
   Negative                            299 (40.6)        82 (40.6)         217 (40.6)       
   Positive                            437 (59.4)        120 (59.4)        317 (59.4)       
  Hospital stay (day)                                    12.7 ± 9.41       10.8 ± 4.92      0.001

Values are presented as mean ± standard deviation or number (%).

CTx, chemotherapy; CEA, carcinoembryonic antigen; DRM, distal resection margin; PRM, proximal resection margin; LN, lymph node.

###### 

Univariate and multivariate analysis with variables affecting disease-free survival

  Variable                                                 Univariate   Multivariate                                  
  -------------------------------------------------------- ------------ -------------- ------- ------- -------------- -------
  Age (≤70 yr vs. \>70 yr)                                 1.790        1.130--2.820   0.013                          
  Sex (male vs. female)                                    0.730        0.450--1.190   0.215                          
  Body mass index                                          1.090        0.840--0.980   0.018   1.100   0.830--0.980   0.014
  Preoperative CEA coding (\<5 ng/mL vs. ≥5 ng/mL)         1.720        1.020--2.910   0.040   1.950   1.190--3.190   0.070
  Obstruction and/or perforation (negative vs. positive)   2.010        1.180--3.420   0.010   3.610   1.400--9.275   0.028
  Postoperative complication (negative vs. positive)       2.120        1.220--3.703   \-                             
  Distal resection margin                                  0.980        0.950--1.018   0.360                          
  Proximal resection margin                                0.996        0.976--1.016   0.715                          
  Harvested LN (\<12 vs. ≥12)                              0.553        0.339--0.904   0.018                          
  Histologic grade (poorly or undifferentiated)            1.100        0.780--1.530   0.570                          
  Neural invasion (negative vs. positive)                  1.070        0.770--1.503   0.660                          
  Vascular invasion (negative vs. positive)                1.690        0.630--4.550   0.290                          
  Lymphatic invasion (negative vs. positive)               0.940        0.690--1.280   0.690                          
  High risk (low vs. high)                                 1.750        1.060--2.880   0.027   \-                     
  Adjuvant CTx (negative vs. positive)                     0.520        0.320--0.840   0.008                          

HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; LN, lymph node; CTx, chemotherapy.

###### 

Univariate and multivariate analysis by variables affecting overall survival

  Variable                                                 Univariate   Multivariate                                   
  -------------------------------------------------------- ------------ --------------- ------- ------- -------------- -------
  Age (≤70 yr vs. \>70 yr)                                 1.820        1.040--3.170    0.034                          
  Sex (male vs. female)                                    0.510        0.270--0.950    0.035   0.449   0.230--0.900   0.025
  Body mass index                                          1.110        0.820--0.990    0.043   1.170   0.760--0.900   0.004
  Preoperative CEA coding (\<5 ng/mL vs. ≥5 ng/mL)         1.780        1.050--3.007    0.030   2.030   1.840--3.830   0.027
  Obstruction and/or perforation (negative vs. positive)   4.085        1.460--11.390   0.010   1.920   1.070--3.430   0.028
  Postoperative complication (negative vs. positive)       1.604        0.770--3.330    0.200                          
  Distal resection margin                                  0.960        0.920--1.012    0.150                          
  Proximal resection margin                                0.960        0.920--1.005    0.080                          
  Harvested LN (\<12 vs. ≥12)                              0.389        0.220--0.690    0.001   0.365   0.190--0.680   0.002
  Histologic grade (poorly or undifferentiated)            2.700        0.370--19.601   0.320                          
  Neural invasion (negative vs. positive)                  0.730        0.310--1.713    0.470                          
  Vascular invasion (negative vs. positive)                0.047        0.000--24.228   0.330                          
  Lymphatic invasion (negative vs. positive)               0.950        0.500--1.790    0.880                          
  High risk (low vs. high)                                 1.770        1.000--3.130    0.027                          
  Adjuvant CTx (negative vs. positive)                     0.770        0.410--1.443    0.042                          

HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; LN, lymph node; CTx, chemotherapy.

###### 

Univariate and multivariate analysis with variables affecting disease-free survival in CTx (+) group and CTx (--) group

  Variable                                                 CTx (+) group   CTx (--) group                                                                                                  
  -------------------------------------------------------- --------------- ---------------- ------- ------- -------------- ------- ------- --------------- ------- ------- --------------- -------
  Age (≤70 yr vs. \>70 yr)                                 1.770           1.050--2.990     0.030                                  2.310   0.790--6.790    0.126                           
  Sex (male vs. female)                                    0.581           0.310--1.080     0.090                                  1.107   0.520--2.340    0.790                           
  Body mass index                                          1.140           0.804--0.978     0.016   1.180   0.707--0.950   0.040   1.030   0.860--1.080    0.610                           
  Preoperative CEA coding (\<5 ng/mL vs. ≥5 ng/mL)         2.010           1.179--3.420     0.010   2.020   1.170--3.460   0.011   1.950   0.807--4.730    0.130                           
  ASA PS classification (I--II vs. III--IV)                1.930           0.700--5.340     0.202                                  3.800   1.200--12.040   0.023   3.420   1.060--11.030   0.039
  Obstruction and/or perforation (negative vs. positive)   0.570           0.280--1.140     0.116                                  0.410   0.180--0.930    0.030                           
  Distal resection margin                                  0.960           0.910--0.980     0.014   0.926   0.870--0.970   0.006   1.002   0.950--1.040    0.920                           
  Proximal resection margin                                0.950           0.910--0.990     0.310                                  1.004   0.970--1.030    0.780                           
  Harvested LN (\<12 vs. ≥12)                              0.970           0.944--1.000     0.049   0.960   0.940--0.990   0.040   0.940   0.940--0.980    0.009   0.960   0.930--1.006    0.100
  Histologic grade (poorly or undifferentiated)            1.200           0.570--2.850     0.550                                  0.640   0.190--2.150    0.470                           
  Neural invasion (negative vs. positive)                  1.250           0.530--2.950     0.606                                  0.930   0.320--2.702    0.903                           
  Vascular invasion (negative vs. positive)                20.860          0.005--86.844    0.475                                  2.160   0.290--15.900   0.440                           
  Lymphatic invasion (negative vs. positive)               0.880           0.390--1.980     0.770                                  0.960   0.360--2.550    0.940                           

CTx, chemotherapy; HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; ASA PS, American Society of Anesthesiologists physical status; LN, lymph node.

###### 

Univariate and multivariate analysis with variables affecting overall survival in CTx (+) group and CTx (−) group

  Variable                                                   CTx (+) group   CTx (--) group                                                                                                   
  ---------------------------------------------------------- --------------- ---------------- ------- ------- --------------- ------- -------- --------------- ------- ------- -------------- -------
  Age (≤70 yr vs. \>70 yr)                                   1.802           0.925--3.515     0.084                                   1.685    0.583--4.875    0.335                          
  Sex (male vs. female)                                      0.490           0.237--1.012     0.054                                   0.621    0.195--1.983    0.422                          
  Body mass index                                            1.150           0.779--0.976     0.017   1.150   0.778--0.979    0.021   0.990    0.842--1.214    0.904                          
  Preoperative CEA coding (\<5 ng/mL vs. ≥5 ng/mL)           1.715           0.853--3.449     0.130                                   2.664    0.748--9.486    0.130                          
  ASA PS classification (I--II vs. III--IV)                  3.782           1.334--10.719    0.012   3.921   1.373--11.197   0.011   2.755    0.760--9.981    0.123                          
  Obstruction and/or perfora- tion (negative vs. positive)   4.381           1.035--18.541    0.045                                   3.370    0.752--15.106   0.112                          
  Distal resection margin                                    1.014           0.953--1.078     0.671                                   0.938    0.881--0.998    0.044                          
  Proximal resection margin                                  0.928           0.854--1.031     0.183                                   0.970    0.923--1.020    0.234                          
  Harvested LN (\<12 vs. ≥12)                                0.629           0.303--1.305     0.213                                   0.131    0.044--0.392    0.000   0.107   0.031--0.374   0.000
  Histologic grade (poorly or undifferentiated)              21.520          0.000--359.48    0.617                                   2.116    0.290--15.454   0.460                          
  Neural invasion (negative vs. positive)                    1.959           0.256--15.013    0.517                                   1.225    0.476--3.151    0.674                          
  Vascular invasion (negative vs. positive)                  22.957          0.005--782.648   0.467                                   20.977   0.003--0.429    0.499                          
  Lymphatic invasion (negative vs. positive)                 2.495           0.550--11.209    0.233                                   0.805    0.396--1.637    0.549                          

CTx, chemotherapy; HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; ASA PS, American Society of Anesthesiologists physical status; LN, lymph node.

###### 

Univariate and multivariate analysis according to variables affecting disease-free survival in high-risk and low-risk groups

  Variable                                                 High-risk group   Low-risk group                                                                                                                                                         
  -------------------------------------------------------- ----------------- ---------------- ------------------------------------------------------- -- -- -- ------- -------------- ------------------------------------------------------- -- -- --
  Age (≤70 yr vs. \>70 yr)                                 1.685             0.954--2.976     0.072                                                            1.761   0.817--3.797   0.149                                                         
  Sex (male vs. female)                                    0.738             0.405--1.344     0.321                                                            0.750   0.343--1.638   0.471                                                         
  Body mass index                                          1.050             0.864--1.054     0.355                                                            1.160   0.760--0.979   0.022^[\*](#tfn1-ac-2018-12-04){ref-type="table-fn"}^         
  Preoperative CEA coding (\<5 ng/mL vs. ≥5 ng/mL)         1.918             1.040--3.535     0.037                                                            1.946   0.883--4.290   0.099                                                         
  ASA PS classification (I--II vs. III--IV)                2.030             0.976--5.436     0.057                                                            2.030   0.480--8.588   0.336                                                         
  Obstruction and/or perforation (negative vs. positive)   2.284             0.903--5.777     0.081                                                                                                                                                 
  Distal resection margin                                  0.928             0.874--0.984     0.013^[\*](#tfn1-ac-2018-12-04){ref-type="table-fn"}^            0.984   0.933--1.038   0.555                                                         
  Proximal resection margin                                0.976             0.932--1.021     0.287                                                            0.958   0.907--1.012   0.127                                                         
  Harvested LN (\<12 vs. ≥12)                              0.802             0.455--1.413     0.446                                                                                                                                                 
  Histologic grade (poorly or undifferentiated)            1.448             0.520--4.033     0.478                                                                                                                                                 
  Neural invasion (negative vs. positive)                  0.482             0.117--1.986     0.312                                                                                                                                                 
  Vascular invasion (negative vs. positive)                1.133             0.615--2.086     0.689                                                                                                                                                 
  Lymphatic invasion (negative vs. positive)               1.318             0.748--2.312     0.339                                                                                                                                                 
  Adjuvant CTx (negative vs. positive)                     0.800             0.398--1.606     0.530                                                            0.781   0.296--2.063   0.618                                                         

HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; ASA PS, American Society of Anesthesiologists physical status; LN, lymph node; CTx, chemotherapy.

P \< 0.05.

###### 

Univariate and multivariate analysis according to variables affecting overall survival in high-risk and low-risk groups

  Variable                                                 High-risk group   Low-risk group                                                                                                     
  -------------------------------------------------------- ----------------- ---------------- --------- ------- -------------- --------- ------- --------------- ------- ------- -------------- -------
  Age (≤70 yr vs. \>70 yr)                                 0.370             0.210--0.640     \<0.000                                    0.990   0.630--1.560    0.990                          
  Sex (male vs. female)                                    0.580             0.320--1.050     0.060     0.241   0.080--0.690   0.008     1.180   0.510--2.730    0.690                          
  Body mass index                                          1.140             0.800--0.970     0.013     1.370   0.610--0.860   \<0.000   1.030   0.850--1.110    0.710                          
  Preoperative CEA coding (\<5 ng/mL vs. ≥5 ng/mL)         1.550             0.830--2.880     0.160                                      2.020   0.760--5.400    0.150                          
  ASA classification (I--II vs. III--IV)                   3.670             1.400--9.650     0.008                                      2.670   0.610--11.560   0.188                          
  Obstruction and/or perforation (negative vs. positive)   0.590             0.330--1.040     0.070                                                                                             
  Distal resection margin                                  0.960             0.920--1.010     0.170                                      1.010   0.960--1.060    0.640                          
  Proximal resection margin                                0.990             0.990--1.008     0.904                                      0.950   0.890--1.010    0.120                          
  Harvested LN (\<12 vs. ≥12)                              0.950             0.920--0.970     0.001     0.940   0.890--0.980   0.017                                                            
  Histologic grade (poorly or undifferentiated)            1.540             0.770--3.070     0.210                                                                                             
  Neural invasion (negative vs. positive)                  1.590             0.800--3.180     0.180                                                                                             
  Vascular invasion (negative vs. positive)                3.850             0.710--5.150     0.180                                                                                             
  Lymphatic invasion (negative vs. positive)               1.200             0.700--1.470     0.560                                                                                             
  Adjuvant CTx (negative vs. positive)                     0.430             0.250--0.750     0.003     0.590   0.330--1.076   0.086     0.860   0.330--2.209    0.760   1.130   0.370--3.410   0.820

HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; ASA, American Society of Anesthesiologists physical status; LN, lymph node; CTx, chemotherapy.
